Paris - Delayed Quote • EUR Euroapi S.A. (EAPI.PA) Follow Compare 3.1100 +0.0100 +(0.32%) As of 3:17:03 PM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations EUROAPI welcomes the French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci to its Puy-de-Dôme site Press Release A tour of Vertolaye manufacturing and storage facilities highlighted EUROAPI’s long-term commitment to health sovereignty Paris and Vertolaye - January 6, 2025 – The French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci visited today EUROAPI’s industrial site in Vertolaye (Puy-de-Dôme), accompanied by members of parliament and local elected representatives. The Vertolaye plant specializes in corticosteroids, EUROAPI moves into a new chapter with new Governance and Leadership Press Release Emmanuel Blin appointed Independent Chair of the Board of DirectorsDavid Seignolle appointed Chief Executive OfficerFull-year 2024 guidance maintained Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company’s Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the reco Olivier Falut appointed EUROAPI’s Chief Financial Officer Press Release Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. “I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in implementing our FOCUS-27 tra EUROAPI closes the financing of its FOCUS-27 plan Press Release Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing the financing of its FOCUS-27 strategic plan. About EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution Press Release €451M Revolving Credit Facility refinanced with a maturity extended to February 2029Issuance of a €200M Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi€54M product capacity reservation for five products and further amendments to the global Manufacturing and Supply Agreement (MSA) agreed with Sanofi “The completion of the financing is an instrumental step in the execution of EUROAPI’s strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “Combined with furth Euroapi SA (EAPIF) (H1 2024) Earnings Call Highlights: Navigating Challenges with Strategic ... Despite a decline in net sales and core EBITDA, Euroapi SA (EAPIF) focuses on strategic projects and financial discipline to drive future growth. EUROAPI - Availability of 2024 Half-Year Financial Report Paris, 05 August, 2024 – EUROAPI posted today its 2024 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2024. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. This report includes notably the 2024 half-year management report, the consolidated financial statements on 30 June 2024, and the Statutory Auditors’ review report on the half-yearly financi H1 2024 Results - Focus-27 strategic plan on track with timely execution of the operational roadmap Press ReleaseParis, 30th July 2024 Net Sales down 9.6% year-on-year – Core EBITDA margin at 10.6%Accelerated commercial momentum with clients other than Sanofi, with Net Sales up 2.9%, excluding the Brindisi site, where production was temporarily suspendedEnhanced effectiveness across the entire organization, with sizeable improvements in industrial efficiencies€10 million Free Cash Flow before financing, driven by strengthened financial disciplineFY 2024 guidance confirmed " Our H1 actions set EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1 Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments and production during Q3 202 EUROAPI and Priothera enter into CDMO collaboration to advance oncology project Press Release EUROAPI and Priothera, a biotechnology company specializing in the treatment of hematological malignancies and the improvement of CAR-T cell therapies, have signed a 5-year CDMO agreementEUROAPI will develop and industrialize the manufacturing process of innovative complex molecule for blood cancers Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules Market update : FOCUS-27 transformation project financing Press release Paris – June 6, 2024 – EUROAPI informs that it has decided to be assisted by a mandataire ad hoc in its discussions initiated in February 2024 regarding the mid-term and long-term financing of its FOCUS-27 strategic transformation project. The mandat ad hoc is an amicable procedure launched at the company's initiative and conducted within a confidential and legally secured framework. EUROAPI has appointed such an independent third party proactively to accelerate the outcome of the EUROAPI reaches major Health IPCEI milestone with official notification from European Commission Press Release Paris – June 6, 2024 – EUROAPI has received official notification from the European Commission that the Company has been selected as one of the 13 companies eligible to share up to EUR 1 billion in total public funding under the Important Project of Common European Interest (IPCEI) dedicated to the pharmaceutical sector, “IPCEI Med4Cure”. This IPCEI had been jointly notified by six Member States of the European Union, i.e. France, Belgium, Hungary, Italy, Slovakia and Spain as a me EUROAPI strengthens its presence in animal health with a €130-150 million supply contract Press Release A 5-year manufacturing contract to support the FOCUS-27 project sales trajectoryThis contract highlights EUROAPI’s know-how and the reliability of its premium Contract Manufacturing Organization services to customers Paris – May 23, 2024 – EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAPI will supply its client with a key veterinary product. The total con Combined General Meeting of May 22, 2024 Press Release Approval of all resolutions put forward by the Board of Directors, including the unconsolidated and consolidated financial statements for the year 2023Ratification of the co-option of Géraldine Leveau as a Director Paris – May 22, 2024 – The Combined General Shareholders’ Meeting of EUROAPI was held on May 22, 2024 in Paris, under the chairwomanship of Viviane Monges, and was attended by all directors. All resolutions put forth to a vote were adopted by the shareholders. The Genera Evelyne Nguyen appointed EUROAPI’s Chief Financial Officer Press Release Paris – May 13, 2024 - Evelyne Nguyen has been appointed EUROAPI’s Chief Financial Officer, effective May 14, 2024, and will be a member of the Executive Committee. She is taking over from Antoine Delcour, who is leaving the company to pursue new endeavors. Antoine will remain within the company until the end of June to ensure a smooth transition. “The entire company and the Board of Directors join me in expressing our sincere gratitude to Antoine for his outstanding dedication to Combined General Meeting of May 22, 2024 - Availability of preparatory documents Press Release Paris – April 30, 2024 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 22, 2024 at 10:00 a.m. (CET) at the Centre de Conférences Verso, 52 rue de la Victoire 75009 Paris.The notice of meeting was published at the French official legal announcement publication (BALO) on Friday April 12, 2024 (bulletin n°45) and the convening notice (avis de convocation) was published in the Actu-juridique.fr, a French journal of legal notice, o EUROAPI streamlines its Executive Committee to improve focus and efficiency Press Release Paris – April 9, 2024 – EUROAPI today announces a streamlining of its Executive Committee around operational functions in order to improve focus and efficiency. This organizational adjustment is part of the transformation of EUROAPI into an innovative API supplier and CDMO with a unique, high-quality and customized product offering. As part of this move, Guillaume Rosso has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre who has decided to pursue other oppo Availability of the 2023 Universal Registration Document, including the Annual Financial Report Press Release Paris – April 5, 2024 – EUROAPI announces the publication of its 2023 Universal Registration Document, filed with the French Autorité des marchés financiers (AMF) on April 5, 2024. The 2023 Universal Registration Document includes in particular: The annual financial report;The Board of Directors’ corporate governance report;The information about social, environmental, and societal responsibility (including the extra-financial performance declaration);The statutory auditors reports, 2023 Universal Registration Document Press Release Paris – March 28, 2024 – EUROAPI today announces that its 2023 Universal Registration Document will be filed with the French Financial Markets Authority (AMF) on April 5, 2024. Financial calendar May 22, 2024: Annual Shareholder General MeetingQ2 2024: Further information on FOCUS-27 projectJuly 31, 2024 (before market opening): H1 2024 Results About EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the wo Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy Press Release Paris – March 14th, 2024 – EUROAPI today announces that its Italian subsidiary, EUROAPI Italy S.R.L., is suspending the production of all APIs1 in Brindisi. Following an internal audit, quality control deficiencies due to potential local misconduct have been identified and are being further investigated. Production will remain suspended until further notice. The relevant health authorities have been informed. The company has initiated a forensic audit and will inform its customers. Performance Overview Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is CAC 40 Return EAPI.PA CAC 40 YTD +10.52% +1.08% 1-Year -48.85% -0.97% 3-Year -75.12% +2.15%